A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
收藏DataCite Commons2026-03-11 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00001491/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC).
提供机构：
Vivli
创建时间：
2018-10-27
